SCG142 TCR-T cells
Phase 1Cell therapy
SCG142 TCR-T cells is one of 34 biologic programs targeting Papilloma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
150 competitors in Papilloma
#DrugCompanyPhaseTrials
1Cervarix
GSKPhase 3
GSK 257049
GSKPhase 3
Comparator: Pbo
Merck & Co.Phase 3
Gardasil
Merck & Co.Phase 3
Havrix
GSKPhase 3
Engerix-B
GSKPhase 3
Taxol
TevaPhase 2
Boostrix
GSKPhase 3
HPV Vaccine
SShanghai Zerun Biotechnology Co.,Ltd
Phase 3
Gardasil9
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SCG142 TCR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details